Vanguard Group Inc Eliem Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 310,486 shares of ELYM stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
310,486
Previous 310,486
-0.0%
Holding current value
$2.39 Million
Previous $838,000
1.43%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ELYM
# of Institutions
21Shares Held
3.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN2.19MShares$16.9 Million4.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL812KShares$6.26 Million0.02% of portfolio
-
Atom Investors LP Austin, TX78.3KShares$603,5070.03% of portfolio
-
Geode Capital Management, LLC Boston, MA66.6KShares$513,6860.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX55.2KShares$425,7690.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $205M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...